Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 21, 2025Fundamental and Clinical PharmacologyOpen Access

Drug Exposure in Chronic Kidney Disease: It Is Not Just About the Glomerular Filtration Rate

View Full Paper
Ask AI
Bookmark
Share

Authors

SLSophie LiabeufJBJessica Berdougo‐TritzLALucie Augey

Discussion

Loading...

Member takes

Overview

Observations highlight altered drug pharmacokinetics and pharmacodynamics in patients with chronic kidney disease, suggesting a need for tailored therapeutic strategies.

Key Points

  • Chronic kidney disease affects over 10% of the population and complicates drug management strategies.
  • Uremic toxins significantly modify drug pharmacokinetics, impacting absorption and bioavailability.
  • Drug distribution and metabolism are altered in CKD, notably reducing cytochrome P450 enzyme expression.
  • These changes may increase drug accumulation and adverse effects, calling for careful monitoring in CKD patients.

Cite This Study

Liabeuf et al. (2025) studied this question.

synapsesocial.com/papers/689a060ee6551bb0af8cd40dhttps://doi.org/10.1111/fcp.70037
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Targeting Uremic Toxins in Chronic Kidney Disease: Current Challenges and Emerging Therapeutic Strategies2026
  2. 2Role of Uremic Toxins, Oxidative Stress, and Renal Fibrosis in Chronic Kidney Disease2024 · 29 citations
  3. 3Gut microbiota alteration in CKD: From toxicity mechanisms to supplementation2024 · 1 citations
  4. 4Non-dialyzable uremic toxins and renal tubular cell damage in CKD patients: a systems biology approach2024 · 2 citations
  5. 5Impact of Uremic Toxins on Endothelial Dysfunction in Chronic Kidney Disease: A Systematic Review2022 · 116 citations